An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.